Novo Nordisk has reported a breakthrough during the testing of drugs for the treatment of type 1 diabetes.
Trial results suggest that its drug Tresiba (insulin degludec) carries a reduced risk of hypoglycaemia episodes compared to Sanofi’s Lantus (insulin glargine).
Tresiba matched Lantus for blood sugar reduction and demonstrated an 11% reduction in the rate of severe or blood glucose confirmed symptomatic hypoglycemia, proven with 2,201 events per 100 patient years for Tresiba, comparing to 2,463 events per 100 patient years for insulin glargine.
Tresiba also reduced the incidences of nocturnal hypoglycaemia by 36% compared with Lantus, at 277 events versus 429.
Executive vice president and chief science officer of Novo Nordisk, Mads Krogsgaard Thomsen, said: “We are very excited about these trial results, which document that Tresiba, also in people with type 1 diabetes, significantly reduces the risk of hypoglycaemia compared to insulin glargine. We expect to initiate filing of the data from the SWITCH trials with regulatory authorities in Q3 2016 with the aim of updating the label for Tresiba.”